Melanoma Institute Australia says it has developed an in-dermatology clinic risk assessment strategy that enables the delivery of personalised melanoma risk estimates with no impact on patient flow.
It’s published data showing the tool was well received by clinicians and patients alike in a trial that incorporated waiting room assessments as part of routine care at the MIA’s dermatology clinic.
Starting in February 2021, the team began issuing iPad-based surveys to all attending patients prior to their appointments, featuring questions from two online risk calculators, other studies and clinical questions.
Answers were used to generate personal scores of lifetime melanoma risk, or, for those people with a previous diagnosis, of developing a subsequent primary invasive or in situ melanoma.
Clinically-trained project managers would then take the patient to a private room, show them a print-out of this information, explain the results, and provide behavioural counselling on prevention and early detection – all before the start of their consultation.
Publishing their results in Cancer Medicine (link here), the study investigators said the study showed the idea had “high feasibility”, although it was believed to be the first to explore the acceptability of providing risk-tailored skin surveillance as part of routine dermatology care.
“Overall, the processes for risk assessment and provision of tailored surveillance recommendations were perceived to enhance patient care,” wrote the study investigators in Cancer Medicine.
“For patients, key facilitators included receiving their personal risk information immediately post- survey completion and in- person, which they found highly acceptable.”
“Patients reported that completing the survey while in the waiting room was a good use of their time and was convenient.”
Reactions from dermatologists and clinic staff, 12 of whom were interviewed as part of the study, were also generally positive.